1. Home
  2. QNCX vs ASMB Comparison

QNCX vs ASMB Comparison

Compare QNCX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNCX
  • ASMB
  • Stock Information
  • Founded
  • QNCX 2012
  • ASMB 2005
  • Country
  • QNCX United States
  • ASMB United States
  • Employees
  • QNCX N/A
  • ASMB N/A
  • Industry
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • ASMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • QNCX Health Care
  • ASMB Health Care
  • Exchange
  • QNCX Nasdaq
  • ASMB Nasdaq
  • Market Cap
  • QNCX 47.7M
  • ASMB 139.8M
  • IPO Year
  • QNCX 2019
  • ASMB 2010
  • Fundamental
  • Price
  • QNCX $1.78
  • ASMB $18.84
  • Analyst Decision
  • QNCX Strong Buy
  • ASMB Strong Buy
  • Analyst Count
  • QNCX 5
  • ASMB 3
  • Target Price
  • QNCX $8.00
  • ASMB $33.00
  • AVG Volume (30 Days)
  • QNCX 320.7K
  • ASMB 43.1K
  • Earning Date
  • QNCX 08-12-2025
  • ASMB 08-07-2025
  • Dividend Yield
  • QNCX N/A
  • ASMB N/A
  • EPS Growth
  • QNCX N/A
  • ASMB N/A
  • EPS
  • QNCX N/A
  • ASMB N/A
  • Revenue
  • QNCX N/A
  • ASMB $32,154,000.00
  • Revenue This Year
  • QNCX N/A
  • ASMB $0.04
  • Revenue Next Year
  • QNCX N/A
  • ASMB N/A
  • P/E Ratio
  • QNCX N/A
  • ASMB N/A
  • Revenue Growth
  • QNCX N/A
  • ASMB 148.33
  • 52 Week Low
  • QNCX $0.51
  • ASMB $7.75
  • 52 Week High
  • QNCX $2.45
  • ASMB $19.93
  • Technical
  • Relative Strength Index (RSI)
  • QNCX 68.77
  • ASMB 66.42
  • Support Level
  • QNCX $1.55
  • ASMB $18.01
  • Resistance Level
  • QNCX $2.05
  • ASMB $19.11
  • Average True Range (ATR)
  • QNCX 0.17
  • ASMB 0.85
  • MACD
  • QNCX 0.02
  • ASMB -0.05
  • Stochastic Oscillator
  • QNCX 64.00
  • ASMB 88.26

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: